Inventions in healthcare
Regenerative Medicine, Medical Devices, Cancer Immunotherapy and rare disease adjuvants
- GN Corporation through inter-disciplinary research with our global network of physicians and scientists have developed a novel cell therapy for male urethral stricture, (BEES-HAUS) successfully tech-transferred to Japan; Further simplified BHES-HAUS as a trial underway.
- Eye-for-eyes-mission clinical study has paved way to help overcome global donor-corneal shortage.
- In medical devices domain, developed (i) a novel bio-inert coating (BLIS-COAT) and (ii) a bio-inert implant (STAR-MING)
- For the rare genetic disease, Duchenne Muscular Dystrophy (DMD), we have developed an immune modulating adjuvant which has been granted Orphan Drug Designation (ODD) and Rare Pediatric Drug Designation (RPDD) by the US FDA.
- Autologous Immune Enhancement- Immune cell Therapy (AIET) for cancer has been successfully tech-transferred to overseas hospitals.
Our core strengths have been, access to and expertise in several unique biomaterials, technologies and products developed and available in Japan, holding potentials to develop new drug candidates, improvised medical devices and novel cell therapy solutions.
About Us
Innovating novel solutions in healthcare using Japanese technologies through international collaboration
GN Corporation since its inception in 2002 in Yamanashi, has been innovating novel solutions in healthcare based on hand-picked original technologies, biomaterials and products originated in Japan, by value adding through phased research from basic to translational and clinical stages in the domains of Regenerative medicine, Medical Devices and Bio-pharmaceuticals -Drug adjuvants for unmet needs.
- Research in cell therapy started in Ophthalmology to develop solutions for corneal damages, got diversified into Urology and Orthopedics.
- Drug adjuvants’ research started with Immune enhancement in Oncology, Immune-cell therapy (AIET), expanded into neurological illnesses, auto-immune diseases in dermatology, gut-brain-axis and rare genetic disease of Duchenne Muscular Dystrophy.
- Medical device initiative started with bio-inert cosmetic implants, extended into improvised coatings.
The founding team with expertise in clinical healthcare delivery systems collaborated with a global network of academicians and industry experts to progress towards worthy social contribution, having been recognized in Japan, is now gearing towards global propagation through Global NICHE Corp, USA.
Founder & Head R&D
Samuel JK. Abraham, MD, PhD, FRCP(L)
Alma mater: Tirunelveli Medical College, India & University of Yamanashi, Japan. Full profile: www.k2k.me
Co-founder & Director
Ms. Yoshiko Amikura, BA (Eng.Lit)
Alma mater: Rikkyo University
Our Strength
Accomplishments & potentials
Affiliated Organizations, events and publications
Latest News
We share updates on our activities, research, academic meetings, and presentations.
Inquiries on Technology Transfer, IP rights Out-licensing & consultancy services
We welcome inquiries even at an early planning stage on:
- Cell therapy tech-transfer
- Collaborative research and translation
- Rare disease candidate-out licensing
- Market research
- Clinical trial coordination
Some images on this website are for illustrative purposes only and may not reflect actual research or clinical settings.